Skip to main content

Table 2 Subgroup analyses for survival at 1, 2, 3, and 5 years

From: Efficacy and safety of re-irradiation for locoregional esophageal squamous cell carcinoma recurrence after radiotherapy: a systematic review and meta-analysis

Outcomes

Factors

Groups

Number of studies

Incidence and 95% CI

P value

I2 (%)

P value for Q statistic

P value between subgroups

1-year survival rate

Sample size

≥ 50

3

0.74 (0.42–1.00)

< 0.001

98.3

< 0.001

< 0.001

  

< 50

4

0.46 (0.15–0.78)

0.004

89.8

< 0.001

 
 

Mean age (years)

≥ 65

4

0.67 (0.41–0.94)

< 0.001

97.1

< 0.001

< 0.001

  

< 65

3

0.44 (0.35–0.53)

< 0.001

0.0

0.622

 
 

Male (%)

≥ 90

3

0.36 (0.04–0.67)

0.026

79.8

0.007

< 0.001

  

< 90

4

0.74 (0.48–1.00)

< 0.001

97.7

< 0.001

 
 

Stage III–IV (%)

≥ 50

3

0.64 (0.21–1.00)

0.004

98.4

< 0.001

< 0.001

  

< 50

3

0.56 (0.19–0.93)

0.003

95.8

< 0.001

 
 

Interval from prior therapy to RT

≥ 24

3

0.79 (0.55–1.00)

< 0.001

90.0

< 0.001

< 0.001

  

< 24

2

0.27 (− 0.04 to 0.57)

0.088

88.0

0.004

 
 

Study quality

Moderate

3

0.86 (0.70–1.00)

< 0.001

90.8

< 0.001

< 0.001

  

Low

4

0.37 (0.18–0.56)

< 0.001

73.5

0.010

 

2-year survival rate

Sample size

≥ 50

3

0.25 (0.10–0.39)

0.001

82.1

0.004

0.576

  

< 50

3

0.26 (0.16–0.36)

< 0.001

0.0

0.743

 
 

Mean age (years)

≥ 65

2

0.34 (0.18–0.50)

< 0.001

68.1

0.077

0.010

  

< 65

4

0.19 (0.13–0.25)

< 0.001

0.0

0.523

 
 

Male (%)

≥ 90

2

0.27 (0.11–0.42)

0.001

0.0

0.444

0.696

  

< 90

4

0.25 (0.14–0.35)

< 0.001

73.5

0.010

 
 

Stage III–IV (%)

≥ 50

2

0.22 (0.13–0.30)

< 0.001

7.2

0.299

0.635

  

< 50

3

0.27 (0.11–0.43)

0.001

80.1

0.006

 
 

Interval from prior therapy to RT

≥ 24

2

0.24 (0.13–0.36)

< 0.001

0.0

0.591

0.006

  

< 24

2

0.18 (0.11–0.24)

< 0.001

0.0

0.430

 
 

Study quality

Moderate

3

0.27 (0.11–0.43)

0.001

80.1

0.006

0.365

  

Low

3

0.21 (0.14–0.28)

< 0.001

0.0

0.558

 

3-year survival rate

Sample size

≥ 50

3

0.29 (0.01–0.57)

0.045

97.6

< 0.001

0.007

  

< 50

2

0.17 (0.07–0.27)

0.001

0.0

0.983

 
 

Mean age (years)

≥ 65

3

0.31 (0.06–0.56)

0.015

95.5

< 0.001

< 0.001

  

< 65

2

0.12 (0.05–0.18)

< 0.001

0.0

0.740

 
 

Male (%)

≥ 90

1

0.17 (− 0.13 to 0.46)

0.273

–

–

0.381

  

< 90

4

0.26 (0.04–0.48)

0.023

96.6

< 0.001

 
 

Stage III–IV (%)

≥ 50

2

0.32 (− 0.08 to 0.73)

0.119

98.7

< 0.001

0.004

  

< 50

2

0.19 (0.12–0.27)

< 0.001

0.0

0.539

 
 

Interval from prior therapy to RT

≥ 24

3

0.30 (0.01–0.59)

0.042

94.3

< 0.001

< 0.001

  

< 24

2

0.16 (0.06–0.26)

0.002

59.9

0.114

 
 

Study quality

Moderate

3

0.31 (0.06–0.56)

0.015

95.5

< 0.001

< 0.001

  

Low

2

0.12 (0.05–0.18)

< 0.001

0.0

0.740

 

5-year survival rate

Sample size

≥ 50

3

0.16 (− 0.03 to 0.35)

0.102

96.4

< 0.001

< 0.001

  

< 50

2

0.12 (− 0.11 to 0.36)

0.294

84.6

0.011

 
 

Mean age (years)

≥ 65

2

0.17 (− 0.12 to 0.46)

0.255

98.5

< 0.001

0.031

  

< 65

3

0.11 (0.01–0.21)

0.032

67.0

0.048

 
 

Male (%)

≥ 90

1

0.26 (0.08–0.44)

0.004

–

–

0.074

  

< 90

4

0.12 (− 0.01 to 0.26)

0.077

96.1

< 0.001

 
 

Stage III–IV (%)

≥ 50

3

0.21 (− 0.01 to 0.42)

0.062

96.5

< 0.001

< 0.001

  

< 50

2

0.05 (− 0.03 to 0.14)

0.215

60.5

0.112

 
 

Interval from prior therapy to RT

≥ 24

2

0.17 (− 0.12 to 0.46)

0.255

98.5

< 0.001

0.009

  

< 24

2

0.06 (0.01–0.12)

0.027

23.4

0.253

 
 

Study quality

Moderate

3

0.15 (− 0.06 to 0.36)

0.156

97.1

< 0.001

0.019

  

Low

2

0.14 (− 0.07 to 0.34)

0.202

80.8

0.023

 
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us